Fatal lupus-like syndrome and ARDS induced by fluvastatin
M K Sridhar, A Abdulla

A woman aged 67 years was admitted to hospital with an 8-week history of polyarthralgia, aches and pains in the muscles, and a generalised rash. She was known to have hypertension, which was controlled with atenolol 50 mg daily. She had a history of retinal-vein thrombosis about 2 years before admission, after which she was placed on aspirin 75 mg daily. A routine screening about 6 months before admission to hospital she was hypercholesteremic, with a serum cholesterol of 7.2 mmol/L. Dietary measures were unsuccessful in lowering her cholesterol and she was placed on fluvastatin 20 mg daily. 1 week after she started the drug she noted an itchy, generalised, erythematous rash, followed by swelling and pain in her right knee and joints of both hands. She discontinued fluvastatin after about 10 weeks, but the symptoms had not resolved after more than 1 month after discontinuation of the drug, and she attended hospital

On admission she looked unwell. Her pulse rate was 92 beats per min; blood pressure 180/100 mm Hg. She was apyrexial. An erythematous maculopapular rash was seen mainly on sun-exposed areas. The facial rash was in a “butterfly” distribution. The small joints of the hands were swollen; there was periangual erythema and telangiectasia. Lung-field assessment showed crackles in both lung bases. Routine serum chemistry showed normal urea and electrolytes, raised concentration of C-reactive protein at 43 mg/L, mild derangement of liver function, and normal serum creatine kinase concentration. Full blood count was normal. Erythrocyte-sedimentation rate was 31 mm in the 1st h. Initial serum autoantibody screen was negative, as was rheumatoid factor; serum complement concentrations were normal; a subsequent test for double-stranded DNA by ELISA was positive at 274 (normal <50). Tests for antithrombin and antinuclear antibodies were negative.

In the first few days after admission the patient became increasingly breathless. Lung-function tests showed a restrictive defect with decreased lung volumes (vital capacity 73% predicted with a normal forced expiratory volume in 1 s/forced vital capacity ratio) and diminished diffusion capacity (59% predicted). Analysis of serial arterial blood gases showed worsening type 1 respiratory failure. Computed tomography of the thorax showed extensive abnormalities of both lung fields, with possible widespread alveolitis and some areas of fibrosis. Bronchoscopy and bronchoalveolar lavage showed no endobronchial abnormality or opportunistic infection. Skin biopsy from an involved area showed a perivascular lymphocytic infiltrate in the dermis and areas of diffuse necrosis within the epidermis with incipient blister formation, features suggestive of subcutaneous lupus and erythema multiforme. An open lung biopsy revealed diffuse alveolar damage with hyaline membrane, intra-alveolar organisation, and atypical respiratory pneumocytes characteristic of drug-induced lung damage, but no evidence of vasculitis or granuloma formation.

Shortly after admission, the patient’s symptoms improved with non-steroidal anti-inflammatory drugs; however, the patient’s respiratory status deteriorated progressively. High-dose steroids (pulsed intravenous methylprednisolone 1 g daily for 3 days) improved her skin lesions but her respiratory status continued to deteriorate. Despite assisted ventilation, and immunosuppressive therapy with cyclophosphamide, she died. At necropsy, the lungs showed signs of adult respiratory distress syndrome (ARDS). There was evidence of coronary atherosoma; a small vegetation of uncertain aetiology was noted on the mitral valve.

In general, statins (HMG Co-A reductase inhibitors) are well tolerated and have been shown to be effective in the primary and secondary prevention of coronary heart disease.12 There have been previous reports of lupus-like syndrome in patients on statins.13 In the cases involving lovastatin14 and simvastatin,15 the symptoms were mild and resolved when the statin was stopped and small doses of oral steroids started. One patient with systemic lupus erythematosus induced by lovastatin had features of pulmonary involvement with radiological appearances of pneumonitis.3 We could not identify previous reports of fatal lupus-like reaction with pulmonary toxicity resulting in an ARDS-like syndrome. No such effects have been reported to the Committee on Safety of Medicine in the UK or manufacturers of statins (personal communications). Our findings may show a class effect rather than an effect restricted to an individual statin. Since the illness was severe and rapidly led to death, it was not possible to fulfill conventional criteria for diagnosis of a drug-induced reaction. The absence of other causes for the clinical syndrome described, previous reports of a similar (albeit milder) cases, the temporal relation of the symptoms to the drug therapy, and the characteristic toxic appearances on lung biopsy argue in favour of an adverse reaction to fluvastatin. A single fatality from a side-effect should not alter prescribing policy, but should lead to greater vigilance and awareness of the potential side-effects and early withdrawal of treatment should suggestives systems occur.

We thank J Parmar for doing the open lung biopsy; S Rogers for his report on the lung biopsy; Gill Doce, Stephanie Mann, and S Humphreys for their report on the skin biopsy, and Valerie Suarez for her necropsy report.


Nutrient Intakes among UK African-Caribbeans: changing risk of coronary heart disease

Sangite Sharma, Janet Cade, Stephen Griffiths, Kennedy Cruklickshank

Coronary heart disease (CHD) mortality in the UK for Caribbean-born people, who are mainly of African descent, continues at less than half the national average for men, and two-thirds for women.1 Nutrient intake is a major contributor to coronary risk but little dietary information is available for the African-Caribbean population in Britain. We developed a specific food-frequency questionnaire (FFQ) with the local African-Caribbean community to assess food consumption during the previous 12 months. This was part of an international study in which a random sample of people aged 25–79 years from four general-practice population registers serving inner-city
results are consistent with the only previous small studies in representative African-Caribbean samples (11 men and 23 women) using weighed-records which found percent energy from fat of 32-6% and 35-8% respectively. The high mean body-mass index in African-Caribbeans, particularly women, suggests that while the quality of the diet is as recommended, quantities consumed are too great for the level of energy expenditure. Increasing percentage energy from fat in the younger compared with older African-Caribbean age group suggests that coronary risk profiles are changing, as other migrant communities have experienced. Notably, in Jamaica, the origin of over 60% of our African-Caribbean population, CHD mortality in 1990 was half that of Caribbean-born people in the UK.

Supported by a European Commission grant to TS3*CT92-0142.


Clinical Epidemiology Unit, University of Manchester Medical School, Manchester M13 9PT, UK (K Cruickshank)

ACE Inhibitors and symptomless dysphagia

Tadashi Arii, Yo Yasuda, Tadatsume Takaya, Satoshi Yoshima, Yasuo Nakashikari, Naoki Yoshimi, Hiroyoshi Fujiiwara

Elderly patients with symptomless dysphagia have decreased cough reflexes. 1 Angiotensin-converting enzyme (ACE) inhibitors induce coughing. We investigated whether a correlation exists between patients with symptomless dysphagia with either cerebral infarction or cerebral haemorrhage and elimination of low serum substance P concentration by ACE inhibitors. 2

16 patients (seven men and nine women) with histories of cerebral infarction or cerebral haemorrhage, all with hypertension and symptomless dysphagia, were classified as group A.

Ten outpatients (six men and four women) on an ACE-inhibitor (imidapril hydrochloride * ) for hypertension, all with no dysphagia, were selected as group B. We also included seven healthy controls. We obtained informed consent from patients or their families.

In patients with cerebral infarction or cerebral haemorrhage, symptomless dysphagia increases at night because the cough reflex is weakened during sleep. 3 To find the occurrence of symptomless dysphagia, we gave 1 mL Technetium Tm CoIloid ("TC") to patients in week A during sleep via a nasal catheter. 4 At 0900 h the next day we checked for symptomless dysphagia by imaging. We had given all patients 5-10 mg daily imidapril hydrochloride orally. We measured serum substance P, bradykinin, and prostaglandin before and 12 weeks after administration. Simultaneous administration of other medications was allowed except for L-dopa. 5

Mean serum substance P was low in group A (group A 23.3 pg/mL, group B 76.5 pg/mL, controls 72.7 pg/mL).